📣 VC round data is live. Check it out!

Pulse Biosciences Valuation Multiples

Discover revenue and EBITDA valuation multiples for Pulse Biosciences and similar public comparables like UFP Technologies, Beijing Balance Medical, Heron Neutron Medical, MicroPort EP and more.

Pulse Biosciences Overview

About Pulse Biosciences

Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled.


Founded

2014

HQ

United States

Employees

75

Financials (LTM)

Revenue: $2M
EBITDA: ($57M)

EV

$2B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Pulse Biosciences Financials

Pulse Biosciences reported last 12-month revenue of $2M and negative EBITDA of ($57M).

In the same LTM period, Pulse Biosciences generated ($151K) in gross profit, ($57M) in EBITDA losses, and had net loss of ($78M).

Revenue (LTM)


Pulse Biosciences P&L

In the most recent fiscal year, Pulse Biosciences reported revenue of $350K and EBITDA of ($50M).

Pulse Biosciences is unprofitable as of last fiscal year, with gross margin of (54%), EBITDA margin of (14419%), and net margin of (20795%).

See analyst estimates for Pulse Biosciences
LTMLast FY202320242025202620272028
Revenue$2M$350K--$350K
Gross Profit($151K)($189K)--($189K)
Gross Margin(10%)(54%)--(54%)
EBITDA($57M)($50M)($42M)($55M)($76M)
EBITDA Margin(3693%)(14419%)--(21677%)
EBIT Margin(4608%)(18791%)--(21983%)
Net Profit($78M)($73M)($42M)($54M)($73M)
Net Margin(5091%)(20795%)--(20795%)

Financial data powered by Morningstar, Inc.

Pulse Biosciences Stock Performance

Pulse Biosciences has current market cap of $2B, and enterprise value of $2B.

Market Cap Evolution


Pulse Biosciences' stock price is $24.26.

Pulse Biosciences share price decreased by 2.9% in the last 30 days, and increased by 60.8% in the last year.

Pulse Biosciences has an EPS (earnings per share) of $-1.05.

See more trading valuation data for Pulse Biosciences
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$2B$2B-1.8%-2.9%12.4%60.8%$-1.05

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Pulse Biosciences Valuation Multiples

Pulse Biosciences trades at 1056.5x EV/Revenue multiple, and (28.6x) EV/EBITDA.

See NTM and 2027E valuation multiples for Pulse Biosciences

EV / Revenue (LTM)


Pulse Biosciences Financial Valuation Multiples

As of June 3, 2026, Pulse Biosciences has market cap of $2B and EV of $2B.

Pulse Biosciences has a P/E ratio of (21.5x).

LTMLast FY202320242025202620272028
EV/Revenuen/mn/m--n/m
EV/EBITDA(28.6x)(32.1x)(38.2x)(29.4x)(21.3x)
EV/EBIT(22.9x)(24.6x)(37.1x)(28.8x)(21.0x)
EV/Gross Profitn/mn/m--n/m
P/E(21.5x)(23.1x)(39.8x)(31.3x)(23.1x)
EV/FCF-(29.7x)(48.8x)(44.4x)(29.7x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Pulse Biosciences Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Pulse Biosciences Margins & Growth Rates

Pulse Biosciences grew revenue by 800% and EBITDA by 29% in the last fiscal year.

In the most recent fiscal year, Pulse Biosciences reported gross margin of (54%), EBITDA margin of (14419%), and net margin of (20795%).

See estimated margins and future growth rates for Pulse Biosciences

Pulse Biosciences Margins

Last FY20252026202720282029
Gross Margin(54%)(54%)(3%)
EBITDA Margin(14419%)(21677%)(2060%)
EBIT Margin(18791%)(21983%)(2449%)
Net Margin(20795%)(20795%)(2701%)
FCF Margin(15559%)(15559%)-

Pulse Biosciences Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth800%--800%
Gross Profit Growth(47%)--(47%)
EBITDA Growth29%30%38%(14%)
EBIT Growth17%29%37%0%
Net Profit Growth17%27%36%17%
FCF Growth-10%49%-

Data powered by FactSet, Inc. and Morningstar, Inc.

Pulse Biosciences Operational KPIs

Pulse Biosciences' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $1.0M for the same period.

Pulse Biosciences' Rule of 40 is (1260%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Pulse Biosciences' Rule of X is (60%) (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Pulse Biosciences
LTMLast FY2025202620272028
Rule of 40(3330%)(1260%)-
Bessemer Rule of X(2785%)(60%)-
Revenue per Employee-$0.0M-
Opex per Employee-$1.0M-
G&A Expenses to Revenue1960%9151%9151%
R&D Expenses to Revenue3413%12777%12777%
Opex to Revenue-21929%21929%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Pulse Biosciences Competitors

Pulse Biosciences competitors include UFP Technologies, Beijing Balance Medical, Heron Neutron Medical, MicroPort EP, 4DMedical, Qingdao Baheal Medical, Draegerwerk, BoneSupport, Oxford Nanopore Technologies and Embla Medical.

Most Pulse Biosciences public comparables operate across Medical Devices, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
UFP Technologies3.0x2.9x15.0x14.4x
Beijing Balance Medical18.2x-45.1x-
Heron Neutron Medical4005.2x-(93.6x)-
MicroPort EP22.3x21.1x117.5x110.9x
4DMedical388.4x325.4x(90.4x)(13.6x)
Qingdao Baheal Medical1.6x1.6x12.8x12.8x
Draegerwerk0.4x0.4x3.9x3.8x
BoneSupport11.9x10.7x57.4x44.0x

This data is available for Pro users. Sign up to see all Pulse Biosciences competitors and their valuation data.

Start Free Trial

Pulse Biosciences VC Funding History

Before going public, Pulse Biosciences raised $8M in total equity funding, across 1 round.

Last private valuation of Pulse Biosciences was $20M, after raising $8M in November 2014.


Pulse Biosciences Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Nov-14Series A-$8M$20MPulse Biosciences completed a business combination on November 6, 2014, acquiring ThelioPulse, Inc., BioElectroMed Corp., and NanoBlate Corp. to consolidate nanosecond pulsed electric fields technology for biomedical applications. A private placement infused the new entity with $8 million in cash and valued it at $20 million total, or $2.67 per share. The company licensed intellectual property from research centers including Old Dominion University, University of Southern California, and BioElectroMed Corp., positioning it to commercialize Nano-Pulse Stimulation (NPS) technology. Pulse Biosciences develops NPS-based systems for electroceutical therapies targeting immuno-oncology, dermatology, and other medical applications. The technology induces cellular responses like immunogenic cell death for tumor treatment and supports tissue treatment across various applications. Post-combination, the company planned research and development to identify markets and improve products ahead of NPS system commercialization. As an early-stage company in 2014, Pulse Biosciences had not generated revenue and relied on equity financing for operations.

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Pulse Biosciences

When was Pulse Biosciences founded?Pulse Biosciences was founded in 2014.
Where is Pulse Biosciences headquartered?Pulse Biosciences is headquartered in United States.
How many employees does Pulse Biosciences have?As of today, Pulse Biosciences has over 75 employees.
Who is the CEO of Pulse Biosciences?Pulse Biosciences' CEO is Paul A. Laviolette.
Is Pulse Biosciences publicly listed?Yes, Pulse Biosciences is a public company listed on Nasdaq.
What is the stock symbol of Pulse Biosciences?Pulse Biosciences trades under PLSE ticker.
When did Pulse Biosciences go public?Pulse Biosciences went public in 2016.
Who are competitors of Pulse Biosciences?Pulse Biosciences main competitors include UFP Technologies, Beijing Balance Medical, Heron Neutron Medical, MicroPort EP, 4DMedical, Qingdao Baheal Medical, Draegerwerk, BoneSupport, Oxford Nanopore Technologies, Embla Medical.
What is the current market cap of Pulse Biosciences?Pulse Biosciences' current market cap is $2B.
What is the current revenue of Pulse Biosciences?Pulse Biosciences' last 12 months revenue is $2M.
What is the current revenue growth of Pulse Biosciences?Pulse Biosciences revenue growth (NTM/LTM) is 363%.
What is the current EV/Revenue multiple of Pulse Biosciences?Current revenue multiple of Pulse Biosciences is 1056.5x.
Is Pulse Biosciences profitable?No, Pulse Biosciences is not profitable.
What is the current EBITDA of Pulse Biosciences?Pulse Biosciences has negative EBITDA and is not profitable.
What is Pulse Biosciences' EBITDA margin?Pulse Biosciences' last 12 months EBITDA margin is (3693%).
What is the current EV/EBITDA multiple of Pulse Biosciences?Current EBITDA multiple of Pulse Biosciences is (28.6x).
How many companies Pulse Biosciences has acquired to date?Pulse Biosciences hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Pulse Biosciences has invested to date?Pulse Biosciences hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Pulse Biosciences

Lists including Pulse Biosciences

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial